scout
Opinion|Videos|January 9, 2025

KEYONTE-522: Exploratory Biomarker Analysis in Periop Pembro vs. Placebo + Chemo

Panelists discuss the exploratory biomarker analysis from the KEYNOTE-522 trial, comparing perioperative pembrolizumab versus placebo plus chemotherapy in early-stage breast cancer, and its implications for treatment strategies.

Newsletter

Stay up to date on practice-changing data in community practice.


Latest CME